Yang, H.; Zhou, Y.; Cheng, X.; Qiu, C.; Wang, S.; Xia, Y.; Huai, X.; Xiu, Z.; Wang, J.; He, Y.;
et al. Safety, Tolerability, and Immunogenicity of a DNA Vaccine (pGX9501) Against SARS-CoV-2 in Healthy Volunteers: A Single-Center, Randomized, Double-Blind, Placebo-Controlled, and Dose-Ranging Phase I Trial. Vaccines 2025, 13, 573.
https://doi.org/10.3390/vaccines13060573
AMA Style
Yang H, Zhou Y, Cheng X, Qiu C, Wang S, Xia Y, Huai X, Xiu Z, Wang J, He Y,
et al. Safety, Tolerability, and Immunogenicity of a DNA Vaccine (pGX9501) Against SARS-CoV-2 in Healthy Volunteers: A Single-Center, Randomized, Double-Blind, Placebo-Controlled, and Dose-Ranging Phase I Trial. Vaccines. 2025; 13(6):573.
https://doi.org/10.3390/vaccines13060573
Chicago/Turabian Style
Yang, Haijing, Yang Zhou, Xin Cheng, Chao Qiu, Shuo Wang, Yu Xia, Xuefen Huai, Zhenning Xiu, Jiarong Wang, Yue He,
and et al. 2025. "Safety, Tolerability, and Immunogenicity of a DNA Vaccine (pGX9501) Against SARS-CoV-2 in Healthy Volunteers: A Single-Center, Randomized, Double-Blind, Placebo-Controlled, and Dose-Ranging Phase I Trial" Vaccines 13, no. 6: 573.
https://doi.org/10.3390/vaccines13060573
APA Style
Yang, H., Zhou, Y., Cheng, X., Qiu, C., Wang, S., Xia, Y., Huai, X., Xiu, Z., Wang, J., He, Y., Cao, G., Wei, Q., Wang, J., Ai, J., Zhang, H., Zhang, Y., Zhang, J., Zhang, W., & Wang, B.
(2025). Safety, Tolerability, and Immunogenicity of a DNA Vaccine (pGX9501) Against SARS-CoV-2 in Healthy Volunteers: A Single-Center, Randomized, Double-Blind, Placebo-Controlled, and Dose-Ranging Phase I Trial. Vaccines, 13(6), 573.
https://doi.org/10.3390/vaccines13060573
